The computation of basic net income per share is based on the number of weighted average shares outstanding during the period. The computation of diluted net income per share includes the dilutive effect of share equivalents consisting of incremental shares deemed outstanding from the assumed exercise of options and unvested restricted stock units ("RSUs"). Performance share awards ("PSAs") are included in the computation of diluted net income per share only to the extent that the underlying performance conditions are satisfied prior to the end of the reporting period or would be satisfied if the end of the reporting period were the end of the related performance period, and if the effect would be dilutive.

A reconciliation of the numerators and denominators of the basic and diluted net income per share calculations is as follows (in thousands, except per share amounts):


	Thirteen weeks ended				Twenty-six weeks ended
	June 28, 2026		June 29, 2025		June 28, 2026		June 29, 2025
Basic net income per share:
Net income	$	129,195	$	133,703	$	292,919	$	313,729
Weighted average shares outstanding - basic	93,988		97,858		94,401		98,198
Basic net income per share	$	1.37	$	1.37	$	3.10	$	3.19
Diluted net income per share:
Net income	$	129,195	$	133,703	$	292,919	$	313,729
Weighted average shares outstanding - basic	93,988		97,858		94,401		98,198
Dilutive effect of share-based awards:
Assumed exercise of options to purchase shares	364		582		354		579
RSUs	58		242		124		364
PSAs	—		92		116		118
Weighted average shares and equivalent shares outstanding - diluted	94,410		98,774		94,995		99,259
Diluted net income per share	$	1.37	$	1.35	$	3.08	$	3.16

For the thirteen weeks ended June 28, 2026, the Company had 0.2 million options, 0.1 million RSUs and 0.3 million PSAs outstanding, which were excluded from the computation of diluted net income per share as those awards would have been antidilutive or were performance awards with performance conditions not yet deemed met. For the thirteen weeks ended June 29, 2025, the Company had 0.1 million options and 0.2 million PSAs outstanding, which were excluded from the computation of diluted net income per share as those awards would have been antidilutive or were performance awards with performance conditions not yet deemed met.

For the twenty-six weeks ended June 28, 2026, the Company had 0.1 million options, 0.1 million RSUs and 0.3 million PSAs outstanding, which were excluded from the computation of diluted net income per share as those awards would have been antidilutive or were performance awards with performance conditions not yet deemed met. For the twenty-six weeks ended June 29, 2025, the Company had 0.1 million options and 0.2 million PSAs outstanding, which were excluded from the computation of diluted net income per share as those awards would have been antidilutive or were performance awards with performance conditions not yet deemed met.